Clinical outcomes of SARS-CoV-2 infection in kidney transplant recipients on belatacept: a single-center experience

Transpl Infect Dis. 2024 Apr;26(2):e14253. doi: 10.1111/tid.14253. Epub 2024 Feb 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Abatacept / therapeutic use
  • COVID-19*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Kidney Transplantation* / adverse effects
  • SARS-CoV-2
  • Transplant Recipients

Substances

  • Abatacept
  • Immunosuppressive Agents